Roberta Frapolli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8573135/publications.pdf

Version: 2024-02-01

75	3,734	182225	150775
papers	citations	30 h-index	59 g-index

79	79	79	7496
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging. Talanta, 2022, 237, 122918.	2.9	9
2	Pharmacokinetic Characterization of the DDAH1 Inhibitors ZST316 and ZST152 in Mice Using a HPLC-MS/MS Method. Molecules, 2022, 27, 1017.	1.7	5
3	Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment. Frontiers in Oncology, 2022, 12, 851790.	1.3	10
4	Inhibition of tumorâ€associated macrophages by trabectedin improves the antitumor adaptive immunity in response to antiâ€PDâ€1 therapy. European Journal of Immunology, 2021, 51, 2677-2686.	1.6	18
5	Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma. Genomics, 2021, 113, 3439-3448.	1.3	2
6	PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. Journal of Experimental and Clinical Cancer Research, 2021, 40, 286.	3.5	18
7	HPLC-MS/MS measurement of lidocaine in rat skin and plasma. Application to study the release from medicated plaster. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1138, 121942.	1.2	2
8	Is DNA repair a potential target for effective therapies against malignant mesothelioma?. Cancer Treatment Reviews, 2020, 90, 102101.	3.4	9
9	Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice. Cancers, 2020, 12, 2136.	1.7	3
10	Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. Cancers, 2020, 12, 2312.	1.7	5
11	Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. International Journal of Biological Sciences, 2020, 16, 1363-1375.	2.6	22
12	Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. British Journal of Cancer, 2019, 121, 464-473.	2.9	7
13	Combination of PPARÎ³ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. Clinical Cancer Research, 2019, 25, 7565-7575.	3.2	15
14	Preclinical Models in Mesothelioma. , 2019, , 85-98.		1
15	Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin. Journal of Controlled Release, 2018, 276, 140-149.	4.8	12
16	Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Scientific Reports, 2018, 8, 948.	1.6	19
17	Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging. Analytica Chimica Acta, 2018, 1042, 1-10.	2.6	7
18	Selfâ€Assembling PCLâ€Based Nanoparticles as PTX Solubility Enhancer Excipients. Macromolecular Bioscience, 2018, 18, e1800164.	2.1	9

#	Article	IF	Citations
19	HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. Oncogene, 2018, 37, 5926-5938.	2.6	24
20	Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. European Journal of Cancer, 2017, 76, 84-92.	1.3	26
21	Application of 3D Mass Spectrometry Imaging to TKIs. Clinical Pharmacology and Therapeutics, 2017, 102, 748-751.	2.3	17
22	Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release. ACS Nano, 2017, 11, 9413-9423.	7.3	44
23	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	13.7	480
24	Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. British Journal of Cancer, 2017, 117, 628-638.	2.9	119
25	Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MKâ€8628 in malignant pleural mesothelioma xenografts. International Journal of Cancer, 2017, 140, 197-207.	2.3	32
26	A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging. Nanomaterials, 2017, 7, 71.	1.9	13
27	The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget, 2017, 8, 7598-7613.	0.8	79
28	Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. Scientific Reports, 2016, 6, 39284.	1.6	68
29	Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Scientific Reports, 2016, 6, 22850.	1.6	36
30	3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors. Scientific Reports, 2016, 6, 37027.	1.6	58
31	Snail levels control the migration mechanism of mesenchymal tumor cells. Oncology Letters, 2016, 12, 767-771.	0.8	9
32	PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers. Molecular Pharmaceutics, 2016, 13, 40-46.	2.3	31
33	Tumor-associated macrophages and anti-tumor therapies: complex links. Cellular and Molecular Life Sciences, 2016, 73, 2411-2424.	2.4	99
34	Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. Molecular Cancer Therapeutics, 2016, 15, 125-135.	1.9	56
35	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget, 2016, 7, 84675-84687.	0.8	42
36	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMPâ€1 and TIMPâ€2 and tumor thrombospondinâ€1. International Journal of Cancer, 2015, 136, 721-729.	2.3	50

#	Article	IF	Citations
37	Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin. British Journal of Cancer, 2015, 113, 1687-1693.	2.9	37
38	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. Connective Tissue Research, 2015, 56, 355-363.	1.1	10
39	Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents. Clinical Cancer Research, 2015, 21, 1373-1382.	3.2	39
40	HPLCâ€“MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model. Bioanalysis, 2015, 7, 1831-1842.	0.6	7
41	Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis. Stem Cell Research, 2015, 15, 243-253.	0.3	19
42	Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors. Biochimie, 2015, 108, 101-107.	1.3	12
43	Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget, 2015, 6, 30072-30087.	0.8	43
44	Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents. , 2015, , .		2
45	A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma. Nanotechnology, 2014, 25, 335706.	1.3	22
46	Mode of action of trabectedin in myxoid liposarcomas. Oncogene, 2014, 33, 5201-5210.	2.6	111
47	Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and ZalypsisÂ® (PM00104). International Journal of Cancer, 2013, 133, 2024-2033.	2.3	54
48	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. Cancer Cell, 2013, 23, 249-262.	7.7	721
49	The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. European Journal of Cancer, 2013, 49, 1142-1151.	1.3	31
50	Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemotherapy and Pharmacology, 2013, 72, 879-887.	1.1	37
51	New activities for the anti-tumor agent trabectedin: taking two birds with one stone. Oncotarget, 2013, 4, 496-497.	0.8	9
52	Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo. Food and Chemical Toxicology, 2012, 50, 1632-1641.	1.8	31
53	Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials. Food and Chemical Toxicology, 2011, 49, 2415-2421.	1.8	68
54	The Neuroprotective Effect of Erythropoietin in Docetaxel-Induced Peripheral Neuropathy Causes No Reduction of Antitumor Activity in 13762 Adenocarcinoma-Bearing Rats. Neurotoxicity Research, 2010, 18, 151-160.	1.3	22

#	Article	IF	Citations
55	The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo. Biochemical Pharmacology, 2010, 79, 1141-1148.	2.0	116
56	Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors. Clinical Cancer Research, 2010, 16, 4958-4967.	3.2	24
57	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. Cancer Research, 2010, 70, 2235-2244.	0.4	251
58	Clinical pharmacokinetics of the new oral camptothecin gimatecan: The inter-patient variability is related to Î±1-acid glycoprotein plasma levels. European Journal of Cancer, 2010, 46, 505-516.	1.3	15
59	Reduced Expression of the ROCK Inhibitor Rnd3 Is Associated with Increased Invasiveness and Metastatic Potential in Mesenchymal Tumor Cells. PLoS ONE, 2010, 5, e14154.	1.1	54
60	Determination of total and lactone form of a new camptothecin derivative gimatecan (ST1481) and its metabolite ST1698 in human plasma by high-performance liquid chromatography with fluorimetric detection. Journal of Pharmaceutical and Biomedical Analysis, 2009, 50, 507-514.	1.4	5
61	The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma. Neoplasia, 2009, 11, 1155-IN7.	2.3	31
62	G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. Clinical Cancer Research, 2008, 14, 7284-7291.	3.2	82
63	Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. British Journal of Cancer, 2007, 97, 888-894.	2.9	49
64	Clindamycinâ€“paclitaxel pharmacokinetic interaction in ovarian cancer patients. Cancer Chemotherapy and Pharmacology, 2006, 58, 319-325.	1.1	17
65	Biological Properties of IDN5174, a New Synthetic Camptothecin with the Open Lactone Ring. Cancer Research, 2006, 66, 10976-10982.	0.4	15
66	Pharmacokinetics and Metabolism in Mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a New Oral C-seco-Taxane Derivative with Antiangiogenic Property Effective on Paclitaxel-Resistant Tumors. Drug Metabolism and Disposition, 2006, 34, 2028-2035.	1.7	18
67	The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: A comparative study with SN38 and topotecan. Biochemical Pharmacology, 2005, 70, 1125-1136.	2.0	26
68	Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22	1.1	11
69	High-performance liquid chromatographic assay for the determination of Aloe Emodin in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 796, 113-119.	1.2	23
70	IDN 5390: an oral taxane candidate for protracted treatment schedules. British Journal of Cancer, 2003, 88, 965-972.	2.9	18
71	Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clinical Cancer Research, 2003, 9, 625-32.	3.2	159
72	Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Research, 2003, 63, 5902-8.	0.4	50

#	Article	IF	Citations
73	Differences between in Vivo and in Vitro Sensitivity to Imatinib of Bcr/Abl+ Cells Obtained from Leukemic Patients. Blood Cells, Molecules, and Diseases, 2002, 28, 361-372.	0.6	27
74	High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 780, 93-98.	1.2	6
75	High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. Biomedical Applications, 1999, 736, 135-141.	1.7	5